Diabetes mellitus is associated with an increased risk for cardiovascular disease, but the link between hyperglycemia and atherothrombotic disease is not completely understood. Patients with diabetes often show hyporesponsiveness to antiplatelet therapies, and it has been suggested that hyperreactive reticulated platelets underlie this altered therapeutic response. In this issue of the
Robert H. Lee, Wolfgang Bergmeier
Neutrophil S100A8/A9 induces TPO production and reticulated thrombocytosis in hyperglycemia.